# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
ABN	098 026 281

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Antony John CARTER
Date of last notice	20 December 2013

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Not Applicable	
Date of change	4 July 2014	
No. of securities held prior to change	<ul> <li>4,748 ordinary shares FNZ Custodians – as custodians for Family Trust</li> <li>62,903 ordinary shares by Loughborough Investments Limited - as Director of Company</li> <li>447,156 ordinary shares – as a Director of Trustee Company – Fisher &amp; Paykel Healthcare Employee Share Purchase Trustee Limited</li> </ul>	
Class	Ordinary shares	
Number acquired	(i) 68 ordinary shares (ii) 911 ordinary shares	
Number disposed	N/A	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	(i) NZ\$309.28 (ii) NZ\$4,097.43	

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	<ul> <li>4,816 ordinary shares FNZ Custodians – as custodians for Family Trust</li> <li>63,814 ordinary shares by Loughborough Investments Limited - as Director of Company</li> <li>650,176 ordinary shares – as a Director of Trustee Company – Fisher &amp; Paykel Healthcare Employee Share Purchase Trustee Limited</li> </ul>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	<ul> <li>(i) Purchase of 68 Ordinary Shares under the Dividend Reinvestment Plan - FNZ Custodians -as custodians for Family Trust;</li> <li>(ii) Purchase of 911 Ordinary Shares under the Dividend Reinvestment Plan - Loughborough Investments Limited - as Director of Company.</li> </ul>

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related	
prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
, ,	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

# Part 3 - + Closed period

Were the interests in the securities or contracts detailed above traded during a + closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
ABN	098 026 281

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Arthur James MORRIS
Date of last notice	12 July 2013

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not Applicable	
Date of change	4 July 2014	
No. of securities held prior to change	Niloc Trust (Family Trust) – 8,785 Ordinary Shares as Trustee and Beneficiary	
Class	Ordinary Shares	
Number acquired	127	
Number disposed	Not Applicable	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	NZ\$572.25	
No. of securities held after change	Niloc Trust (Family Trust) – 8,912 Ordinary Shares as Trustee and Beneficiary	

<sup>+</sup> See chapter 19 for defined terms.

Nature of change  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Purchase of 127 Ordinary Shares under the Dividend Reinvestment Plan.
---	---

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 - + Closed period

Were the interests in the securities or contracts	No
detailed above traded during a + closed period where prior written clearance was required?	
·	
If so, was prior written clearance provided to	Not applicable
allow the trade to proceed during this period?	
If prior written clearance was provided, on what	Not applicable
date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
ABN	098 026 281

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Donal Paul O'DWYER
Date of last notice	20 December 2013

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Not Applicable
Date of change	4 July 2014
No. of securities held prior to change	53,202 as Trustee of the Dundrum Super Fund
Class	Ordinary Shares
Number acquired	829
Number disposed	Not Applicable
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	A\$3,219.81

+ See chapter 19 for defined terms.

No. of securities held after change	54,031 Ordinary Shares as Trustee of Dundrum Super Fund
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Purchase of 829 Ordinary Shares under the Dividend Reinvestment Plan – Dundrum Super Fund.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
_	
(if issued securities)	
Date of change	
Date of change	
No. and class of securities to	
which interest related prior to	
change	
Note: Details are only required for a contract in	
relation to which the interest has changed	
Interest acquired	
miorosi asquirsa	
Interest disposed	
V-1/0	
Value/Consideration	
Note: If consideration is non-cash, provide details and	
an estimated valuation	
Interest after change	
Interest after change	

## Part 3 - + Closed period

Were the interests in the securities or contracts	No
detailed above traded during a + closed period	
where prior written clearance was required?	
If so, was prior written clearance provided to	Not Applicable
allow the trade to proceed during this period?	
If prior written clearance was provided, on what	Not Applicable
date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
ABN	098 026 281

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MICHAEL GRENFELL DANIELL
Date of last notice	9 June 2014

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Not Applicable	
Date of change	4 July 2014	
No. of securities held prior to change	<ul> <li>Daniell Family Trust – 758,116 Trustee &amp; Beneficiary</li> <li>Michael Grenfell Daniell – 26,851 ordinary shares</li> <li>Michael Grenfell Daniell – 800,000 options to acquire ordinary shares</li> <li>Michael Grenfell Daniell – 60,000 Performance Share Rights</li> <li>Fisher &amp; Paykel Healthcare Employee Share Purchase Trustee Ltd – Director of Trustee Company 650,176 ordinary shares</li> </ul>	
Class	Ordinary Shares	
Number acquired	i) 10,993 ii) 389	
Number disposed	Not applicable	

<sup>+</sup> See chapter 19 for defined terms.

Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	i) NZ\$49,382.83 ii) NZ\$1,749.04	
No. of securities held after change	<ul> <li>Daniell Family Trust – 769,109 Trustee &amp; Beneficiary</li> <li>Michael Grenfell Daniell – 27,240 ordinary shares</li> <li>Michael Grenfell Daniell – 800,000 options to acquire ordinary shares</li> <li>Michael Grenfell Daniell – 60,000 Performance Share Rights</li> <li>Fisher &amp; Paykel Healthcare Employee Share Purchase Trustee Ltd – Director of Trustee Company 650,176 ordinary shares</li> </ul>	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Dividoria (Controdiction)	

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which interest	
related prior to change	
Note: Details are only required for a contract	
in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide	
details and an estimated valuation	
Interest after change	

### Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

<sup>+</sup> See chapter 19 for defined terms.

NZX X	
Ongoing Disclosure Notice	
Disclosure of Directors and Officers Relevant Interests	
Section 19T(2), Securities Markets Act 1988	
A Details of director or officer	A
Name of director or officer of public issuer:	Antony John CARTER Fisher & Paykel Healthcare Corporation
Name of public issuer:	Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in public issuer:	Director
B Securities in public issuer or any related body corporate in which director or officer has relevant interest	
Number, class, and type of securities:	(i) 68 Ordinary Shares (ii) 911 Ordinary Shares
C Nature of relevant interest and name of registered holder	
Nature of relevant interest in securities:	Beneficial Ownership
Name of registered holder of securities	(i) Antony Carter Family Trust No 2 (ii) Loughborough Investments Limited
D Details of acquisitions and disposals	
If the relevant interest was acquired—	
Date of acquisition:	4 July 2014
Consideration paid for acquisition:	(i) NZ\$309.28
Oursideration paid for acquisition.	(ii) NZ\$4,097.43
If the relevant interest was disposed of—	
Date of disposal:	Not Applicable
Consideration received for disposal:	Not Applicable
Type of transaction	
Describe the arrangement pursuant to which, or the circumstances in which, the acquisition or disposal took place:	Purchase of 979 Ordinary Shares under the Dividend Reinvestment Plan
E Total number of transactions this notice relates to:	Two
F Date of last disclosure notice (whether in form 1 or form 2) by the director or officer:	20 December 2013
G Signature	
Signature of director or officer:	Alel
Date of signature:	11 July 2014
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
-	
Name and title of authorised person:	

NZX X	
Ongoing Disclosure Notice	
Disclosure of Directors and Officers Relevant Interests	
Section 19T(2), Securities Markets Act 1988	
A Details of director or officer  Name of director or officer of public issuer:	Arthur James MORRIS
·	Fisher & Paykel Healthcare Corporation
Name of public issuer:	Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in public issuer:	Director
B Securities in public issuer or any related body corporate in which director or officer has relevant interest	
Number, class, and type of securities:	127 Ordinary Shares
C Nature of relevant interest and name of registered holder	
Nature of relevant interest in securities:	Beneficial Ownership
Name of registered holder of securities	Niloc Trust
D Details of acquisitions and disposals	
If the relevant interest was acquired—	
Date of acquisition:	4 July 2014
Consideration paid for acquisition:	NZ\$572.25
If the relevant interest was disposed of—	
Date of disposal:	Not Applicable
Consideration received for disposal:	Not Applicable
Type of transaction	
Describe the arrangement pursuant to which, or the circumstances in which, the acquisition or disposal	Purchase of 127 Ordinary Shares under
took place:	the Dividend Reinvestment Plan.
	One
E Total number of transactions this notice relates to:	
F Date of last disclosure notice (whether in form 1 or form 2) by the director or officer:	20 December 2013
G Signature	
Signature of director or office:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	3
Date of signature:	11 July 2014
	Antony George Barclay
Name and title of authorised person:	Company Secretary

NZX X	
Ongoing Disclosure Notice	
Disclosure of Directors and Officers Relevant Interests	
Section 19T(2), Securities Markets Act 1988	
A Details of director or officer	
Name of director or officer of public issuer:	Donal Paul O'DWYER
Name of public issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in public issuer:	Director
B Securities in public issuer or any related body corporate in which director or officer has relevant interest	
Number, class, and type of securities:	829 Ordinary Shares
C Nature of relevant interest and name of registered holder	
Nature of relevant interest in securities:	Beneficial Ownership
Name of registered holder of securities	Dundrum Super Fund
D Details of acquisitions and disposals	1
If the relevant interest was acquired—	4 July 2014
Date of acquisition:	4 July 2014
Consideration paid for acquisition:	A\$3,219.81
If the relevant interest was disposed of—	
Date of disposal:	Not Applicable
Consideration received for disposal:	Not Applicable
Type of transaction	
Describe the arrangement pursuant to which, or the circumstances in which, the acquisition or disposal took place:	Purchase of 829 Ordinary Shares under the Dividend Reinvestment Plan
E Total number of transactions this notice relates to:	One
F Date of last disclosure notice (whether in form 1 or form 2) by the director or officer:	20 December 2013
G Signature	
Signature of director or office:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	8
Date of signature:	11 July 2014
Name and title of authorised person:	Antony George Barclay
Traine and the or authorised person.	Company Secretary

NZX X	
Ongoing Disclosure Notice	
Disclosure of Directors and Officers Relevant Interests	
Section 19T(2), Securities Markets Act 1988	
A Dateila of director or officer	
A Details of director or officer  Name of director or officer of public issuer:	Michael Grenfell DANIELL
Name of public issuer:	Fisher & Paykel Healthcare Corporation
·	Limited
Name of related body corporate (if applicable):  Position held in public issuer:	Not Applicable  Managing Director/Chief Executive Officer
Totale in public locus.	managing birottor, and Exceptive officer
B Securities in public issuer or any related body corporate in which director or officer has relevant interest	
Number, class, and type of securities:	(i) 10,993 Ordinary Shares (ii) 389 Ordinary Shares
C Nature of relevant interest and name of registered holder	
Nature of relevant interest in securities:	Beneficial Ownership
Name of registered holder of securities	(i) Daniell Family Trust (ii) Michael Grenfell Daniell
D Details of acquisitions and disposals	
If the relevant interest was acquired—	
Date of acquisition	4 July 2014
Consideration paid for acquisition	(i) NZ\$49,382.83 (ii) NZ\$1,749.04
If the relevant interest was disposed of—	N
Date of disposal	Not applicable
Consideration received for disposal	Not applicable
Type of transaction	
Describe the arrangement pursuant to which, or the circumstances in which, the acquisition or disposal took place	Purchase of 11,382 ordinary shares under the Dividend Reinvestment Plan
E Total number of transactions this notice relates to	Two
F Date of last disclosure notice (whether in form 1 or form 2) by the director or officer	9 June 2014
G Signature	
Signature of director or office:	wooriel
Date of signature:	11 July 2014
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	